In this article, Dr. Gerardo Villarreal Berain and Dr. Rebeca Castillo Del Ángel present a structured scientific review comparing the clinical outcomes of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in the management of metabolic and cardiovascular conditions.

Both therapies have revolutionized the treatment landscape for obesity and type 2 diabetes. However, emerging evidence suggests their benefits go far beyond weight loss. This review analyzes key findings from recent high-impact trials published between 2021 and 2024, with a focus on:

• Body weight reduction
• Prevention and remission of type 2 diabetes
• Improvement in lipid profile (cholesterol, triglycerides, HDL)
• Osteoarthritis and musculoskeletal pain
• Sleep apnea severity (AHI)
• Hospitalizations due to heart failure

The article includes a visual comparative table (Figure 1) summarizing outcomes and dosages, helping clinicians make informed decisions based on current evidence.